Propranolol blocks cardiac and neuronal voltage-gated sodium channels

Frontiers in Pharmacology

Volumn DEC, Issue , 2010, Pages

  Wang, Dao W ^a,b   Mistry, Akshitkumar M ^a   Kahlig, Kristopher M ^a   Kearney, Jennifer A ^a   Xiang, Jizhou ^b   George, Alfred L ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Propranolol; SCN1A; SCN2A; SCN3A; SCN5A; Sodium channel

Indexed keywords

EID: 84858795442     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2010.00144     Document Type: Article

References (37)

1. Ahrens-Nicklas, R. C., Clancy, C. E., and Christini, D. J. (2009). Re-evaluating the efficacy of β-adrenergic agonists and antagonists in long QT-3 syndrome through computational modeling. Cardiovasc. Res. 82, 439-447.
2. Ayata, C., Jin, H., Kudo, C., Dalkara, T., and Moskowitz, M. A. (2006). Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. 59, 652-661.
3. Bankston, J. R., and Kass, R. S. (2010). Molecular determinants of local anesthetic action of beta-blocking drugs: implications for therapeutic management of long QT syndrome variant 3. J. Mol. Cell. Cardiol. 48, 246-253.
4. Bennett, P. B., Yazawa, K., Makita, N., and George, A. L. Jr. (1995). Molecular mechanism for an inherited cardiac arrhythmia. Nature 376, 683-685.
5. Benson, D. W., Wang, D. W., Dyment, M., Knilans, T. K., Fish, F. A., Strieper, M. J., Rhodes, T. H., and George, A. L. Jr. (2003). Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J. Clin. Invest. 112, 1019-1028.
6. Bigal, M. E., and Lipton, R. B. (2009). The epidemiology, burden, and comorbidities of migraine. Neurol. Clin. 27, 321-334.
7. Casucci, G., Villani, V., and Frediani, F. (2008). Central mechanism of action of antimigraine prophylactic drugs. Neurol. Sci. 29(Suppl. 1), S123-S126.
8. Chronicle, E., and Mulleners, W. (2004). Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst. Rev. 3, CD003226.
9. Dawson, A. K., Reele, S. B., Wood, A. J., Duff, H. J., Woosley, R. L., and Smith, R. F. (1984). Electrophysiological effects of high-dose propranolol in dogs: evidence in vivo for effects not mediated by the beta adrenoceptor. J. Pharmacol. Exp. Ther. 229, 91-97.
10. Desaphy, J. F., Pierno, S., De Luca, A., Didonna, P., and Camerino, D. C. (2003). Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders. Mol. Pharmacol. 63, 659-670.
11. Duff, H. J., Roden, D. M., Brorson, L., Wood, A. J., Dawson, A. K., Primm, R. K., Oates, J. A., Smith, R. F., and Woosley, R. L. (1983). Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. J. Am. Coll. Cardiol. 2, 1134-1140.
12. Fabritz, L., Damke, D., Emmerich, M., Kaufmann, S., Theis, K., Blana, A., Fortmuller, L., Laakmann, S., Hermann, S., Aleynichenko, E., Steinfurt, J., Volkery, D., Riemann, B., Kirchhefer, U., Franz, M. R., Breithardt, G., Carmeliet, E., Schafers, M., Maier, S. K., Carmeliet, P., and Kirchhof, P. (2010). Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3. Cardiovasc. Res. 87, 60-72.
13. Fischer, W. (2002). Anticonvulsant profile and mechanism of action of propranolol and its two enantiomers. Seizure 11, 285-302.
14. Gellens, M. E., George, A. L., Chen, L., Chahine, M., Horn, R., Barchi, R. L., and Kallen, R. G. (1992). Primary structure and functional expression of the human cardiac tetrodotoxininsensitive voltage-dependent sodium channel. Proc. Natl. Acad. Sci. U.S.A. 89, 554-558.
15. Gleiter, C. H., and Deckert, J. (1996). Adverse CNS-effects of beta-adrenoceptor blockers. Pharmacopsychiatry 29, 201-211.
16. Jaeger, V., Esplin, B., and Capek, R. (1979). The anticonvulsant effects of propranolol and beta-adrenergic blockade. Experientia 35, 80-81.
17. Kahlig, K. M., Saridey, S. K., Kaja, A., Daniels, M. A., George, A. L. Jr., and Wilson, M. H. (2010). Multiplexed transposon-mediated stable gene transfer in human cells. Proc. Natl. Acad. Sci. U.S.A. 107, 1343-1348.
18. Kangasniemi, P., and Hedman, C. (1984). Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia 4, 91-96.
19. Lauritzen, M. (1994). Pathophysiology of the migraine aura. The spreading depression theory. Brain 117, 199-210.
20. Linde, K., and Rossnagel, K. (2004). Propranolol for migraine prophylaxis. Cochrane Database Syst. Rev. 2, CD003225.
21. Lossin, C., Wang, D. W., Rhodes, T. H., Vanoye, C. G., and George, A. L. Jr. (2002). Molecular basis of an inherited epilepsy. Neuron 34, 877-884.
22. McAinsh, J., and Cruickshank, J. M. (1990). Beta-blockers and central nervous system side effects. Pharmacol. Ther. 46, 163-197.
23. Mehvar, R., and Brocks, D. R. (2001). Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J. Pharm. Pharm. Sci. 4, 185-200.
24. Misra, S. N., Kahlig, K. M., and George, A. L. Jr. (2008). Impaired NaV1.2 function and reduced cell surface expression in benign familial neonatal-infantile seizures. Epilepsia 49, 1535-1545.
25. Moss, A. J., Zareba, W., Hall, W. J., Schwartz, P. J., Crampton, R. S., Benhorin, J., Vincent, G. M., Locati, E. H., Priori, S. G., Napolitano, C., Medina, A., Zhang, L., Robinson, J. L., Timothy, K., Towbin, J. A., and Andrews, M. L. (2000). Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 101, 616-623.
26. Murray, K. T., Reilly, C., Koshakji, R. P., Roden, D. M., Lineberry, M. D., Wood, A. J., Siddoway, L. A., Barbey, J. T., and Woosley, R. L. (1990). Suppression of ventricular arrhythmias in man by d-propranolol independent of betaadrenergic receptor blockade. J. Clin. Invest. 85, 836-842.
27. Olsson, J. E., Behring, H. C., Forssman, B., Hedman, C., Hedman, G., Johansson, F., Kinnman, J., Palhagen, S. E., Samuelsson, M., and Strandman, E. (1984). Metoprolol and propranolol in migraine prophylaxis: a double-blind multicentre study. Acta Neurol. Scand. 70, 160-168.
28. Priori, S. G., Napolitano, C., Schwartz, P. J., Grillo, M., Bloise, R., Ronchetti, E., Moncalvo, C., Tulipani, C., Veia, A., Bottelli, G., and Nastoli, J. (2004). Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 292, 1341-1344.
29. Ragsdale, D. S., McPhee, J. C., Scheuer, T., and Catterall, W. A. (1994). Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science 265, 1724-1728.
30. Schoenen, J., Maertens de Noordhout, A., Timsit-Berthier, M., and Timsit, M. (1986). Contingent negative variation and efficacy of beta-blocking agents in migraine. Cephalalgia 6, 229-233.
31. Schulze-Bahr, E., Fenge, H., Etzrodt, D., Haverkamp, W., Monnig, G., Wedekind, H., Breithardt, G., and Kehl, H. G. (2004). Long QT syndrome and life threatening arrhythmia in a newborn: molecular diagnosis and treatment response. Heart 90, 13-16.
32. Schwartz, P. J., Priori, S. G., Spazzolini, C., Moss, A. J., Vincent, G. M., Napolitano, C., Denjoy, I., Guicheney, P., Breithardt, G., Keating, M. T., Towbin, J. A., Beggs, A. H., Brink, P., Wilde, A. A., Toivonen, L., Zareba, W., Robinson, J. L., Timothy, K. W., Corfield, V., Wattanasirichaigoon, D., Corbett, C., Haverkamp, W., Schulze-Bahr, E., Lehmann, M. H., Schwartz, K., Coumel, P., and Bloise, R. (2001). Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 103, 89-95.
33. Silberstein, S. D. (2000). Practice parameter: evidence-based guidelines for migraine headache (an evidencebased review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55, 754-762.
34. Wang, D. W., Crotti, L., Shimizu, W., Pedrazzini, M., Cantu, F., De Filippo, P., Kishiki, K., Miyazaki, A., Ikeda, T., Schwartz, P. J., and George, A. L. Jr. (2008). Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel. Circ. Arrhythm. Electrophysiol. 1, 370-378.
35. Wang, D. W., Desai, R. R., Crotti, L., Arnestad, M., Insolia, R., Pedrazzini, M., Ferrandi, C., Vege, A., Rognum, T., Schwartz, P. J., and George, A. L. Jr. (2007). Cardiac sodium channel dysfunction in sudden infant death syndrome. Circulation 115, 368-376.
36. Wang, D. W., Viswanathan, P. C., Balser, J. R., George, A. L. Jr., and Benson, D. W. (2002). Clinical, genetic, and biophysical characterization of SCN5A mutations associated with atrioventricular conduction block. Circulation 105, 341-346.
37. Woosley, R. L., Kornhauser, D., Smith, R., Reele, S., Higgins, S. B., Nies, A. S., Shand, D. G., and Oates, J. A. (1979). Suppression of chronic ventricular arrhythmias with propranolol. Circulation 60, 819-827.